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Objectives: The study aimed to develop evidence-based recommendations for the 
treatment of rapidly progressive interstitial lung disease (RPILD) associated with the 
anti-Melanoma Differentiation-Associated Gene 5-positive dermatomyositis (DM) 
syndrome.  
Methods: The task force comprised an expert panel of specialists in rheumatology, 
intensive care medicine, pulmonology, immunology, and internal medicine. The study 
was carried out in two phases: identifying key areas in the management of DM-RPILD 
syndrome and developing a set of recommendations based on a review of the available 
scientific evidence. Four specific questions focused on different treatment options were 
identified. Relevant publications in English, Spanish or French up to April 2018 were 
searched systematically for each topic using PubMed (MEDLINE), EMBASE, and 
Cochrane Library (Wiley Online). The experts used evidence obtained from these 
studies to develop recommendations. 
Results: A total of 134 studies met eligibility criteria and formed the evidentiary basis 
for the recommendations regarding immunosuppressive therapy and complementary 
treatments. Overall, there was general agreement on the initial use of combined 
immunosuppressive therapy. Combination of high-dose glucocorticoids and calcineurin 
antagonists with or without cyclophosphamide is the first choice. In the case of 
calcineurin antagonist contraindication or treatment failure, switching or adding other 
immunosuppressants may be individualized. Plasmapheresis, polymyxin B 
hemoperfusion and/or intravenous immunoglobulins may be used as rescue options. 
ECMO should be considered in life-threatening situations while waiting for a clinical 
response or as a bridge to lung transplant. 
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Conclusions: Thirteen recommendations regarding the treatment of the anti-MDA5 
positive DM-RPILD were developed using research-based evidence and expert opinion.  
Word count: 248 
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Idiopathic inflammatory myopathies are a heterogeneous group of systemic 
autoimmune diseases usually characterized by inflammatory infiltrates in the muscle 
biopsy. Several phenotypes are included, being dermatomyositis (DM) one of the best 
recognized
1
. The autoantibody profile allows individualizing the clinical presentations 
in DM patients being some manifestations linked to specific autoantibodies. This is the 
case of the clinically amyopathic dermatomyositis (CADM) with anti-melanoma 
differentiation-associated gene 5 (MDA5) antibodies
2
. Those are patients with the 
characteristic skin rash of the disease, with Gottron’s papules and heliotrope sign, but 
without muscle weakness, herein the name of clinically amyopathic DM. The 
distribution of classic DM and CADM in anti-MDA5 positive patients varies among 
ethnic groups, being CADM around 82% in Japan and between 42-50% in non-Japanese 
patients
3-5
. At least three different subsets of DM positive for anti-MDA5 antibodies can 
be identified
6-9
, a cutaneous form without muscle or lung involvement, a chronic form 
of cutaneous features with interstitial lung disease resembling the antisynthetase 
syndrome, and lastly the most severe form of cutaneous manifestations with rapidly 
progressive ILD (RPILD). Patients with DM anti-MDA5 with RPILD usually have a 
bad prognosis, and, although mortality figures may vary among different ethnicities
10, 
11
, up to 80% of these patients do not survive even after an early diagnosis or intensive 
immunosuppressive therapy
12
. Therefore, the aim of this study, with the participation of 
the different areas of knowledge implicated in its treatment (i.e. intensive care unit, 
rheumatology, pulmonology, immunology and internal medicine) is to provide 
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evidence-based recommendations on the different treatments until now used in these 
patients in order to define which will be the best treatment to offer, and to define an 
algorithm of actuation.  
Recommendations’ Questions 
In order to address our objective, the main clinical question formulated was, 1) “Which 
is the effectiveness, efficacy, and safety of the different treatments administered in anti-
MDA5 positive CDM-RPILD patients?” 
However, given that scarce scientific evidence on the matter was expected, and that 
some CDM patients with RPILD were reported before the detection of antiMDA5 
antibodies was available, the Expert Panel decided to analyze also other groups of 
related conditions. Thus, three additional clinical questions were formulated to prepare 
the scientific evidence search strategy and further facilitate the reaching of our 
objective: 
2. Which is the effectiveness, efficacy, and safety of the different treatments 
administered in anti-MDA5 positive patients with non-RPILD or other type of ILD such 
as usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), or 
cryptogenic organizing pneumonia (COP)? 
3. Which is the effectiveness, efficacy, and safety of the different treatments 
administered in patients with inflammatory myopathy and RPILD negative to or with 
unknown status of anti-MDA5 antibodies? 
4. Which is the effectiveness, efficacy, and safety of the different treatments 
administered in RPILD anti-MDA5 negative antibody patients with systemic 
autoimmune diseases other than dermatomyositis? 
 
Methods 
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Study design. A qualitative synthesis of the scientific evidence currently 
available was performed. Consensus techniques of methodology were used to collect 
expert opinion based on the participants' clinical experience when only no or low-
quality scientific evidence was available. 
 Study stages. This study has been developed according to the different stages for 
elaborating Clinical Practice Guidelines (CPG) in the Spanish National Health 
System
13
. The process was divided into seven different stages. 
 Recommendations of the working group. The guidelines working group made up 
of 7 healthcare professionals from different disciplines in the area of myositis and 
progressive interstitial lung disease (rheumatology, internal medicine, intensive care 
medicine, immunology and pulmonology). The expert group has been managed by a 
clinical and methodological coordination team. The different Scientific Societies 
involved were contacted agreeing to be represented in the development group. 
 Identification of key areas. The expert group defined the main objectives of the 
recommendations. They identified those clinical questions expected to have the greatest 
impact on the management of DM-RPILD syndrome in MDA5 positive patients. 
 Analysis of scientific evidence. The research question was formulated according 
to the Population, Intervention, Comparison, Outcome (PICO) format. The question 
related to Lung transplantation was not framed in the PICO format, and was based on a 
non-systematic review of the studies published on the topic. A systematic literature 
review was performed in PubMed (MEDLINE), EMBASE (Elsevier), and Cochrane 
Library (Wiley Online) until April 2018; subsequently the expert group identified some 
studies which had been published till July 2019 and were included in the evidence 
corpus. The search strategy was constructed by an experienced medical librarian; 
included studies published in English, Spanish or French and were limited to studies in 
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humans. The search strategy was developed initially in PubMed using controlled 
vocabulary and free text terms, and then it was adapted for each of the other databases 
to find publications about “interstitial lung diseases” and synonyms. Articles were 
excluded if they were (1) meeting abstracts not subsequently published in peer-reviewed 
journals; (2) editorials, commentaries and narrative reviews. Additional information 
about the search strategy can be consulted as on-line supplementary material (available 
in the Data Supplement). 
 Analysis and summary of scientific evidence. Evaluation of the quality of the 
studies and summary of the evidence for each question was performed using the critical 
reading tool of the Agency for Healthcare Technology Assessment of the Basque 
Country (OSTEBA)
14
. Furthermore, the determination of the evidence levels and the 
recommendations grade was based on SIGN methodology (Scottish Intercollegiate 
Guidelines Network)
13
. (Appendix 1). 
 Formulation of recommendations.  Formulation of recommendations was based 
on the “formal evaluation” or “justified opinion” of SIGN
13
. To determine the strength 
of each one of the formulated recommendations, the development group has considered 
not only the level of evidence available but also the equilibrium between desirable and 
undesirable consequences of carrying out the recommendation. The good clinical 
practice recommendations have been formulated and agreed by consensus following a 
transparent methodology with a face-to-face meeting of the development group and a 
subsequent series of successive consultation rounds with a panel of experts. These 
recommendations have been divided into four complementary areas: general 
management, combination therapy, therapy for the refractory patient and other 
therapeutic options (Table 1).  
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 External review. External reviewers have participated in the review of the 
second draft. The purpose of submitting the CPG to external review was to improve the 
overall quality, to ensure the appropriateness of recommendations, to disseminate the 
evidence, as well as to assess its applicability and feasibility. 
 Public Display. The draft of recommendations was subject to public comment 
by the Spanish Society of Rheumatology associate members and different interest 
groups (the pharmaceutical industry, other scientific societies, and patient associations). 
The objective was to collect scientific input on the methodology and recommendations 
put forth by the document. 
 
Conflicts of Interest 
All members of the Expert Panel completed the disclosure form, which requires 
disclosure of financial and other interests, including relationships with commercial 
entities that are reasonably likely to experience direct regulatory or commercial impact 
as a result of promulgation of the guideline. Categories for disclosure include 
employment; leadership; stock or other ownership; honoraria, consulting or advisory 
role; speaker’s bureau; research funding; patents, royalties, other intellectual property; 
expert testimony; travel, accommodations, expenses; and other relationships. In 
accordance with the Policy, the majority of the members of the expert panel did not 
disclose any relationships constituting a conflict under the Policy. 
 
Overarching principles 
Diagnostic accuracy and rationale of the different questions, methods of anti-MDA5 
detection and brief description of the different therapies administered 
         
 
10 
Not generally accepted diagnostic criteria for patients with the anti-MDA5 
syndrome do exist. Therefore, most studies included patients with definite or probably 
DM, usually clinically amyopathic, and antibodies positive to MDA5 detected using 
home-made ELISA or blot, protein immunoprecipitation or commercial tests such as 
EUROIMMUNE. Altogether RPILD was considered when worsening of radiologic 
interstitial changes with progressive dyspnea and hypoxemia within 1 month after the 
onset of respiratory symptoms appeared. The diagnosis of ILD was established by chest 
X-ray and/or high-resolution CT scan showing reticular opacities, ground-glass opacity 
(GGO) or honeycomb appearance
15
.  
 One of the proposed strategies to treat properly these patients includes risk 
stratification. In this setting, it is important to evaluate those parameters that can act as 
an activity surrogate. Although a myriad of biomarkers has been described
16
, ferritin is 
the most recognized factor. Hoa et al
17
 found in a series of MDA5 (+) RP-ILD 
associated DM, that levels of ferritin were in the range of 370-13,878 ng/ml (NV < 200 
ng/ml). Blood values higher than 1,000 ng/ml, seem to be associated with higher 
mortality in Caucasians and Asian ethnicities
18-21
; moreover, ferritin values run in 
parallel to the activity of the disease
22
. Beside the ferritin, Krebs von den Lungen-6 
(KL-6), a type II pneumocyte glycoprotein has been postulated as a biomarker of ILD in 
different ethnicities
23, 24
. Nevertheless, although in anti-MDA5 (+) patients the value of 
KL6 is high, it does not correlate with activity, treatment response, or mortality
20, 22, 25, 
26
. Values of C reactive protein higher than 1 mg/dL and age older than 60 years seem 
to be risk factors of bad prognosis
11
.  Finally, several articles focused on the level of the 
anti-MDA5 values measured using ELISA test. Higher values of anti-MDA5 antibodies 
correlate with a worst outcome
16, 20, 27, 28
 and seem to be a good biomarker of relapse
22
. 
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The different therapies that have been administered to these patients are 
described in Table 2. 
 
Results 
By the search strategy, 134, 134, 1164, and, 3132 references were respectively 
identified. Of these, 49, 8, 30, 13 full-text papers respectively were included in the 
systematic review. A detailed flow chart with the results of the literature search is 
shown in Appendix 2. 
General Management 
Recommendation 1: Patients with DM-associated rapidly progressive interstitial lung 
disease anti-MDA5 (+) should be treated with combination therapy as a first option. 
(Recommendation grade D). 
Scientific evidence on efficacy and safety of the drugs used for the treatment of 
anti-MDA5 (+) associated RPILD comes from observational studies and case reports. 
All the identified studies include a combined or progressive administration of 
immunosuppressive drugs with or without support therapies. The usual approach 
comprises a combined schedule of glucocorticoids (oral prednisone or prednisolone, 
intravenous methylprednisolone pulse therapy, or both), immunosuppressive drugs 
(intravenous cyclophosphamide or calcineurin antagonists such as cyclosporine A or 
tacrolimus), and intravenous immunoglobulin as an adjuvant therapy
10, 16-19, 22, 28-51
  
(Level of evidence 3). 
Obtained data is mainly focused on mortality and prognosis factors that 
contribute to an interstitial pneumonia favorable outcome. In summary, all the studies 
gave support to the combination therapy. Accordingly, and considering their clinical 
expertise, the elaborating group also supports combination therapy as the best available 
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Recommendation 2: A combination therapy including glucocorticoids plus a 
calcineurin antagonist (cyclosporine A or tacrolimus), or triple therapy adding 
intravenous cyclophosphamide to the previous schedule, are both considered good 
initial alternatives. (Recommendation grade D). 
Recommendation 2a: Both, cyclosporine A and tacrolimus are considered equally good 
therapeutic options. The choice of any of them will depend on the safety profile and 
patients’ characteristics. (Recommendation grade √). 
Recommendation 2b: Monitoring of calcineurin antagonists blood levels is 
recommended to adjust posology and minimize toxicity (Recommendation grade √). 
A systematic review of the scientific evidence allowed us to identify several 
observational studies (case series) focused on the pharmacological combination therapy 
in patients with DM-associated RPILD and anti-MDA5 positive antibodies.  
Three retrospective studies
16, 19, 37
 aimed to analyze the differences in clinical 
activity and pulmonary function parameters between patients with anti-MDA5 positive 




, included 20 RPILD anti-MDA5 (+) patients, 12 of them 
received treatment with a combination of prednisolone and cyclophosphamide plus 
calcineurin antagonists (triple therapy). Seven out of 12 (58%) died and the other 5 
(42%) developed a favorable outcome and survived. Eight patients received treatment 
with a combination of prednisolone and either cyclophosphamide or a calcineurin 
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antagonist (2 died and 6 survived). The number of patients treated with the combination 
including a calcineurin antagonist is not specified.  
At the second study
19
 the authors identify 17 anti-MDA5 positive patients who 
develop RPILD among a series of 95 DM patients. In this study only one (16%) out of 6 
patients who received triple therapy (prednisolone, cyclophosphamide and calcineurin 
antagonists) died. Among the other 11 who were treated with a combination therapy 
including prednisolone plus either cyclophosphamide or calcineurin antagonists, 3 
(27%) died.  
Finally, the third of the 3 retrospective studies previously mentioned
37
 included 
12 patients diagnosed with DM anti-MDA5 positive who develop a RPILD. Eight of 
these patients received combination therapy with prednisolone and cyclosporine, and 
only 3 (25%) died. The other 4 patients received triple therapy (prednisolone, 




 analyzed 11 patients positive to anti-MDA5 with RPILD, who 
were also treated with triple therapy, being tacrolimus the calcineurin inhibitor used. A 
good clinical response was noticed and none of the patients died, although a non-
significant trend to clinical relapse was observed in those patients who received a 
reduced number of intravenous cyclophosphamide cycles (Level of evidence 3). 
Hozumi et al
40
 reported 15 patients diagnosed with DM anti-MDA5 positive and 
ILD, 13 of them with anti-MDA5 positive and RPILD. Ten were treated with 
combination therapy that included prednisolone plus a calcineurin antagonist 
(cyclosporine in 8 patients and tacrolimus in 2), and 5 received a triple therapy scheme 
(prednisolone, cyclophosphamide and cyclosporine). Six out of 15 patients died, 5 of 
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them due to respiratory failure and the other one of unknown cause (Level of evidence 
3). 
Other 4 retrospective studies adding indirect evidence were identified. Patients 
reported in these studies were mostly but not all anti-MDA5 positive, and there was no 
specific information for this subgroup. Tanizawa et al
39
 included 12 anti-MDA5 
positive patients, five of whom developed RPILD. Seven out of the 12 patients died, 
five of them with RPILD, being six of them treated with triple therapy (glucocorticoid, 
cyclophosphamide and cyclosporine) and the other one with the combination of 
glucocorticoids and cyclosporine. Ikeda et al
34
 reported 10 patients positive to anti-
MDA5 who developed ILD, 6 (60%) of them died, all with the RPILD phenotype, even 
though they received triple therapy. Ma X et al
35
, reported 7 MDA5 positive patients 
with RPILD, being treated with triple therapy including mycophenolate, leflunomide, 
intravenous immunoglobulin, and some naturist therapies (i.e. Chinese herbs). Six out 
of 7 (85%) died. A study published by Nakashima, et al
10
, compare a cohort of 14 
MDA5 patients who develop RPILD and were treated with triple therapy (prednisolone, 
cyclophosphamide and cyclosporine) with a historical cohort who received standard 
therapy (not described). Mortality in the group treated with triple therapy was 25% in 
comparison with 71.4% of the historical cohort (Level of evidence 3). 
Overall, published data are scarce and the level of evidence of the studies is 
weak. Hence, case reports were also included in the analysis, with a total of 53 anti-
MDA5 positive DM patients with RPILD. The outcome of the reported cases that were 
treated with combination therapy (glucocorticoids, plus either cyclophosphamide or 
cyclosporine, or a combination of both immunosuppressive drugs)
28-32, 36, 38 
was good, 
and only 2 cases died
30, 36
. Other reported cases that used tacrolimus instead of 
cyclosporine
33, 41-43, 45, 46
, also had a good prognosis, except for two cases
45, 46
 and one 
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out of the three reported cases in the Koguchi-Yoshioka H et al study
42
 (Level of 
evidence 3). 
 In summary, from the analysis of the reported cases, 21 patients (40%) died, and 
32 (60%) improved after immunosuppressive therapy. Most cases received combination 
therapy with glucocorticoids (either oral prednisone or prednisolone or pulsed 
methylprednisolone), cyclophosphamide and/or a calcineurin antagonist (cyclosporine 
or tacrolimus). Outcome data, in terms of mortality, on this combination therapies from 
retrospective studies and case reports are summarized in table 3.  
  Two more published cases that included from the onset mycophenolate added to 
the combination therapy of glucocorticoid and calcineurin antagonists were identified. 
One is the case number 9 from Hoa et al
17
 who presented a good outcome after being 
treated with mycophenolate, tacrolimus and glucocorticoids, and the other one (case 9) 
with RPILD reported by Takada et al
44
 developed a progressive course and died in spite 
of triple therapy with glucocorticoid, mycophenolate and cyclosporine (Level of 
evidence 3). 
 The expert group, therefore, considers that there is no enough information for a 
triple therapy recommendation including mycophenolate plus glucocorticoids and 
calcineurin antagonists from the disease onset.  
 Lastly, other studies providing indirect information have been identified. They 
included patients diagnosed with DM and negative for or with unknown anti-MDA5 
antibodies status, who developed a RPILD. Combination therapy (glucocorticoid and 
calcineurin antagonists from the onset) effectively reduced mortality in comparison with 
historical controls treated only with glucocorticoids, mainly in those patients with acute 
ILD (6.7% vs. 28.6%, p=0.043) and (31% vs. 68%, p=0.049)
16, 19
. Moreover, those DM 
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patients with acute or subacute ILD who received triple therapy with glucocorticoids, 
cyclophosphamide and cyclosporine, had a survival of 50%
40, 44
. 
Improvement of pulmonary function parameters, creatine-kinase and manual 
muscle test (MMT) score and a reduction in glucocorticoid requirement with an 
increase in disease-free survival (HR: 0.25; CI 95% 0.010-0.66, p=0.005)
34, 35
 was 
observed when tacrolimus was added to the standard immunosuppressive therapy 
(prednisolone and/or cyclophosphamide and/or cyclosporine). (Level of evidence 3). 
 Considering these results, the expert group stated that the first therapeutic option 
in anti-MDA5 positive patients with RPILD is a combination therapy including 
glucocorticoids plus the administration of a calcineurin antagonist, or alternatively a 
triple therapy with glucocorticoids, calcineurin antagonists and pulses of intravenous 
cyclophosphamide. If cyclophosphamide is not feasible, the administration of 
mycophenolate may be a good option. 
Otherwise, although studies performed in myositis patients with RPILD, 
negative for or with unknown anti-MDA5 antibodies, suggest that adding tacrolimus to 
other immunosuppressive drugs (glucocorticoids and/or cyclophosphamide and/or 
cyclosporine) may improve the outcome of these patients, the evidence is so scarce that 
it does not allow to establish a preference for tacrolimus over cyclosporine. 
 Although cyclosporine A has been the most commonly used calcineurin 
antagonist in patients with RPILD and positive anti-MDA5 antibodies, and the benefits 
of adding tacrolimus to other immunosuppressive drugs have not been specifically 
evaluated, the expert group considered that the choice of tacrolimus or cyclosporine will 
depend on the safety profile and the patient clinical background. 
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Recommendation 3: When calcineurin antagonists are not feasible, consider 
combination therapy with glucocorticoids and other immunosuppressive drugs such as 
cyclophosphamide and/or mycophenolate mofetil, or adding rituximab to any one of the 
previous schedules (Recommendation grade 3). 
Recommendation 3a: The choice of one of these drugs will depend on the individual 
characteristics of the patient and the clinician experience (Recommendation grade √). 
Double therapy with glucocorticoid and cyclophosphamide was used in several 
retrospective studies and case reports. Two retrospective studies previously mentioned 
in recommendation 2
16, 19
 describe 19 cases (8 and 11 patients, respectively) treated with 
a double therapy combining glucocorticoid and cyclophosphamide or a calcineurin 
antagonist, 14 patients of whom survived (6 and 8, respectively). The number of 
patients treated with the combination including cyclophosphamide is not specified. 
Besides, the case reported by Goussot
32
 received this double therapy and also survived 
(Level of evidence 3).  
 The evidence about the efficacy and safety of mycophenolate in the treatment of 
RPILD associated with anti-MDA5 is scarce and indirect, based on 12 patients from 
case series and reports
47-50, 52
. Mycophenolate was combined with other 
immunosuppressants resulting in three patients who died and nine with clinical 
improvement. Six out of nine patients who improved did not receive calcineurin 
antagonists as part of the therapeutic strategy. Two of the three patients who died 
received sequential treatment with several immunosuppressants, which did not include 
calcineurin antagonists
48, 49
 (Level of evidence 3).  
In assessing these results, the expert panel considered that when calcineurin 
antagonists are not feasible, either double therapy with glucocorticoid and 
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cyclophosphamide or mycophenolate or triple therapy with the three of them with or 
without intravenous immunoglobulins might also be a valid therapeutic option.  
Thirteen patients treated with rituximab due to RPILD associated to anti-MDA5 
antibodies have been reported. Six of them did not receive calcineurin antagonists as 
part of the combined therapy with cyclophosphamide with or without mycophenolate
17, 
47-49, 53
. Of these, four patients died
17, 48, 49
 and only two improved
47, 53
 (Level of evidence 
3). According to these data, the expert panel considers that adding rituximab to the 
combination of glucocorticoid and cyclophosphamide must be taken with caution.  
 
Therapy for the refractory patient  
Recommendation 4: In patients with DM-associated rapidly progressive interstitial 
lung disease anti-MDA5 (+) who do not respond to combination therapy with 
glucocorticoids plus immunosuppressive drugs, clinicians have to consider the 
following alternatives:  
- Adding one of these immunosuppressive drugs (cyclophosphamide, 
mycophenolate mofetil, rituximab, basiliximab or tofacitinib) to the current 
therapy (Recommendation grade D) 
- Change one immunosuppressant for another (Recommendation grade √) 
Although definition of a refractory patient can differ from one study to another, 
it is generally accepted as a lack of response after administration of the classic 
therapeutic schedule following recommendations 2 and 3. Some studies have defined 
treatment failure in these patients when they fulfill the following conditions at least 1 
week after the institution of triple therapy: deteriorating respiratory symptoms; 
increasing alveolo-arterial O2 tension difference (A-aDO2); newly-emerging or 
expanding GGO/consolidation on chest imaging; increasing ferritin levels, and the 
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Evidence-based analysis identified several drugs used as rescue therapy in 
refractory patients with anti-MDA5 positive DM-associated RPILD. Rituximab has 
been added to the standard immunosuppressive therapy (recommendations 1 and 2) in 
patients with RPILD impairment
17, 48, 49, 53, 55-59
. Eight out of 13 reported patients died, 
even though rituximab had been added
17, 48, 49, 55, 59
, and 5 improved
17, 53, 56, 57
, although 
in a single case relapse did not involve the lung
47
 (Level of evidence 3). 
As previously reported, recommendations 2 and 3 gather the available evidence 
(case reports) on the use of mycophenolate in combination with other 
immunosuppressive drugs. Only a single patient refractory to the initial triple therapy 
that finally improved after adding mycophenolate has been identified
50
 (Level of 
evidence 3). 
A single study highlighted the efficacy of basiliximab (an anti-CD25/sIL-2R 
monoclonal antibody)
60
. It included 4 patients who were refractory to 
immunosuppressive therapy including prednisone, cyclosporine, and intravenous 
immunoglobulin. Basiliximab showed efficacy in 3 of the 4 patients
60
 (Level of evidence 
3) 
Another option in the case of failure to the conventional triple therapy is to 
replace one immunosuppressant for another. Nevertheless, in the case of calcineurin 
antagonists, Yoshida et al
46
 described the case of a patient refractory to triple 
immunosuppressive therapy who died despite switching cyclosporine by tacrolimus 
(Level of evidence 3). 
Finally, two studies have found a good response adding the Janus kinase 
inhibitor tofacitinib to conventional triple therapy in six refractory cases. Kurasawa et 
al
54
 reported a survival rate of 60% in tofacitinib-treated patients (three out of five) 
compared to none out of six historical controls with similar poor-prognostic factors. 
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However, 80% of tofacitinib-treated patients presented varicella-zoster virus 
reactivation and 100% developed cytomegalovirus infection. Kato et al
61
 reported a case 
of refractory ILD with pneumomediastinum responsive to tofacitinib add-on therapy 
(Level of evidence 3). 
Considering these results, the expert group suggests that in refractory cases to 
standard triple immunosuppressive therapy (recommendations 2 and 3), adding to a new 
immunosuppressant or switching one for another may be considered valid therapeutic 
alternatives. 
 
Recommendation 5: In patients who do not respond to combined immunosuppressive 
drugs, the use of the following alternative rescue therapies, either separate or in a 
sequential manner, might be considered: 
- Polymyxin B hemoperfusion (Recommendation grade D) 
- Plasmapheresis (Recommendation grade D) 
- Intravenous immunoglobulins (Recommendation grade √) 
 
Use of non-pharmacologic therapies such as polymyxin B, plasmapheresis or 
intravenous immunoglobulin (IVIg) administration is accepted as rescue therapy in 
these patients. Adsorption and elimination of inflammatory cytokines, mediators and 
activated leukocytes, as well as removing anti-MDA5 antibodies could be the rationale 




 aimed to evaluate the efficacy of polymyxin B 
hemoperfusion analyzed 14 clinically amyopathic dermatomyositis associated RPILD 
patients (10 with anti-MDA5 antibodies). Before polymyxin B use, all the patients have 
been treated with standard triple therapy including prednisolone, cyclophosphamide and 
calcineurin antagonists (cyclosporine or tacrolimus). Polymyxin B administration was 
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performed by using a polymyxin B-immobilized fiber column and conventional 
equipment for hemoperfusion and hemodialysis circuit. Nine out of 10 (90%) of anti-
MDA5 positive patients died, and only one case survived (Level of evidence 3). 
Takada et al
44
 reported in a retrospective study 2 out of 13 patients diagnosed 
with CADM and positive anti-MDA5 antibodies refractory to combined 
immunosuppressive therapy in whom polymyxin hemoperfusion was performed; one of 
them survived.  
Four more patients refractory to conventional immunosuppressive therapy have 
also been published
63-66
 reporting a significant improvement when polymyxin 
hemoperfusion was added. Ichiyasu et al
67
 described 3 cases of CADM with RPILD 
who responded to polymyxin B hemoperfusion after previous failure of triple 
combination immunosuppressive therapy (cyclophosphamide pulses, cyclosporine and 
glucocorticoids), although the anti-MDA5 status was not reported. The same author    
reported a study of 77 patients diagnosed with RPILD, 41 being treated with polymyxin 
B hemoperfusion in comparison with 36 from a historical control group. They found a 
90-day reduced mortality in the polymyxin group vs the historical group (41.5% vs 
66.7%, p=0.019).  Half of the patients studied were diagnosed with connective tissue 





 published a series of 24 patients 
with an acute exacerbation of interstitial pneumonia, 12 of them were DM, who were 
negative for anti-MDA5 antibodies. Data reported in this study showed a better outcome 
of those patients in whom polymyxin hemoperfusion was performed, although it did not 
reduce the mortality. Nevertheless, only one out of 5 DM patients in whom polymyxin 
B hemoperfusion was performed died in comparison with 6 out of 7 who did not receive 
this therapy (p=0.045). Therefore, direct hemoperfusion using a polymyxin B-
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immobilized fiber column after triple standard immunosuppressive therapy, even in 
patients negative to anti-MDA5 antibodies, may support the potential use of this 
technique as a rescue therapy in this clinical setting (Level of evidence 3). 
Considering this data, and that a third (5 out of 14, 35%) of RPILD anti-MDA5 
positive patients who received polymyxin hemoperfusion as an add-on therapy to the 
triple immunosuppressive therapy survived, the expert group made a favorable 
recommendation. 
Ten patients treated with plasmapheresis
12, 48, 55, 64, 69
 have been identified. All 
the reported cases included this therapy as additional treatment to triple conventional 
combined/progressive immunosuppressive schedule. Only 2 patients survived, and one 
of them also received also polymyxin hemoperfusión
64, 69 (Level of evidence 3).  
Taking into account the above reported data, the expert group suggests that 
plasmapheresis may be included as a part of the scheduling approach in patients with 
anti-MDA5 positive and RPILD. 
Intravenous immunoglobulin rescue therapy is usually administered as an 
adjuvant therapy. A total of 22 patients with anti-MDA5 positive RPILD associated DM 
were retrieved from published case reports, more than half of them (13 out of 22, 59%) 
were alive at the end of the therapy, which was usually combination of different 
immunosuppressive drugs and glucocorticoids. Ma et al
35
 in a single study reported 7 
out of 11 anti-MDA5 positive patients with pneumomediastinum and RPILD who 
received treatment with IVIgs. No information on the specific outcome in those 7 
patients was reported. 
Although there is not enough data to support that IVIgs are useful as a direct 
therapy for anti-MDA5 positive rapidly progressive ILD associated DM, the expert 
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panel agreed on that IVIgs should be considered as a potential useful adjuvant treatment 
(Recommendation grade √). 
Recommendation 6: Assistance with veno-venous extracorporeal membrane 
oxygenation (VV-ECMO) should be considered in patients with life-threatening severe 
and refractory respiratory insufficiency to maintain the patient alive while waiting for a 
clinical response to intensive and combined immunosuppressive treatment or as a 
bridge to lung transplantation (Recommendation grade √). 
Veno-venous extra-corporeal Membrane Oxygenation (VV-ECMO), a method of life 
support used to oxygenate the blood is a technique aimed to provide prolonged 
respiratory support in those patients with respiratory failure. VV-ECMO assistance can 
maintain lung function during days or weeks. Nevertheless, it is a complex procedure 
and consumes high human and technical requirements that only should be performed in 
high specialized centers. It is considered the very last therapeutic option when standard 
therapy had failed, and always as a bridge to a definitive solution of the original cause 
of respiratory failure. 
The use of VV-ECMO in refractory anti-MDA5 positive DM patients that 
develop RPILD is exceptional and it has only been described in 6 studies. Among them, 
a retrospective study
12
 reported 6 patients with refractory respiratory failure who 
received VV-ECMO as organ support. However, despite this procedure, all (100%) of 
them finally died. Alqatari et al
55
 and Gorka et al
70
 reported 2 cases that developed a 
poor outcome and died. In contrast, Broome et al
71
 and Leclair et al
72
 reported the case 
of a middle-aged man with anti MDA5-associated RPILD refractory to 
immunosuppressants who was treated with ECMO for 52 days as a bridge therapy to 
successful bilateral lung transplant. More recently, Deitchman et al
73
 and Huang et al
74
 , 
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reported one and three refractory patients, respectively, who also survived after VV-
ECMO bridging to lung transplant (Level of evidence 3). 
 Taking together all this information, the expert panel considered that the use of 
ECMO as life support may be effective in anti-MDA5 positive patients who develop 
RPILD while a complete response to combination immunosuppressive therapy has not 
yet been achieved or as a bridge therapy to lung transplantation. 
 
Recommendation 7: Lung transplantation should be considered as a therapeutic option 
in patients with refractory RPILD associated with anti-MDA5. Early referral for 
transplant eligibility assessment is recommended at the time of ILD diagnosis 
(Recommendation grade √). 
In patients with interstitial lung disease associated with connective tissue disease 
(CTD), lung transplantation is contraindicated at many centers because of the impact of 
pre-existing conditions on post-transplant outcomes. Potential contributors to poor 
outcomes include gastroesophageal reflux (thought to cause bronchiolitis obliterans 
syndrome), renal disease (as it complicates management of immunosuppressive and 
antimicrobial agents commonly used after transplantation), and extra-pulmonary disease 
such as myositis (which complicates management of immunosuppression and 
rehabilitation after transplantation and the risk of malignancy association). In fact, less 
than 1% of all lung transplants worldwide between 1995 and 2015 were given to 
patients with CTD associated with lung disease
75
. However, recent studies suggest that 
post-transplant outcomes in these patients do not differ significantly from those in 
patients with non-CTD
76-78
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Data on lung transplantation in anti-MDA5 positive DM associated RPILD are 
scarce and limited to case series and reports. Selva-O’Callaghan et al
80
 reported two 
cases of unsuccessful lung transplantation in patients with DM-associated RPILD 
complicated with pneumomediastinum, subcutaneous emphysema and acute alveolar 
injury. Several years later, stored serum samples of these patients, which were obtained 
at the beginning of the disease, were analyzed. They turned out to be positive for anti- 
MDA 5 antibodies (author personal communication). On the other hand, Shoji et al
81
 
reported a case of bilateral living-donor lobar lung transplantation with uneventful 
postoperative course, who also was able to perform daily activities without oxygen 
seven months after surgery. Besides, a patient reported by Leclair et al
72
, who 
underwent bilateral lung transplantation after prolonged VV-ECMO, was able to resume 
his normal life with a survival period to date of twelve years in remission. More 
recently, a patient reported by Deitchman et al
73
 and three out of eight anti-MDA5 
positive RPILD refractory patients reported by Huang et al
74
 survived after lung 
transplant being previously supported by VV-ECMO. (Level of evidence 3). 
Therefore, the expert panel strongly recommends referring soon patients with 
ILD associated with anti-MDA5 antibodies to centers with experience in the evaluation 
and management of lung transplantation in CTD.  
 
Other treatment options 
Recommendation 8: Azathioprine, methotrexate and leflunomide are not recommended 
as an induction therapy in RPILD associated with anti-MDA5 antibodies 
(Recommendation grade √). 
 The evidence about the efficacy and safety of azathioprine in RPILD associated 
with anti-MDA5 is scarce with uneven results in the only five reported cases. With 
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respect to this, two patients received azathioprine as part of sequential therapy with non-
calcineurin antagonists immunosuppressants (cyclophosphamide, mycophenolate and 
rituximab) but they did not survive
48, 49
. However, case 5 of the Hoa series
17
 who 
developed pleural effusion, improved after adding azathioprine to glucocorticoid and 
tacrolimus double therapy. Finally, azathioprine monotherapy plus glucocorticoid 
resulted in ILD improvement in one case
82
 and fatal outcome in another
83
 (Level of 
evidence 3).    
 Information about the use of methotrexate in anti-MDA5-associated ILD has 
only been retrieved from seven patients with the non-RP form. In all of them, 
methotrexate was used as part of the combined treatment with other 
immunosuppressants (mycophenolate, hydroxychloroquine, azathioprine, or rituximab). 
All patients presented a good clinical course without progression of the pulmonary 
involvement
8, 84
. Both, the scarce number of patients and the association with other 
immunosuppressants make difficult to evaluate the real effect of methotrexate in the 
observed outcome (Level of evidence 3).  
 Leflunomide has only been evaluated in seven patients with anti-MDA5-
associated RPILD
35
. It was used in combination with Chinese herbs and other 
immunosuppressants, including glucocorticoid, cyclophosphamide, calcineurin 
antagonists, mycophenolate and intravenous immunoglobulins, thus being very difficult 
to evaluate, in this context, the role of this drug in the fatal outcome of 6 out of the 7 
patients (85%) (Level of evidence 3). 
Considering the results of all these studies and the scarce clinical experience, the 
elaborating group considered that azathioprine, methotrexate and leflunomide should 
not be recommended in the management of RPILD, particularly as an induction therapy. 
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Recommendation 9: Infliximab is not recommended in MDA-5 associated RPILD 
treatment (Recommendation grade √).  
 Regarding the use of infliximab in inflammatory myopathy-associated RPILD, 
only a retrospective case series of fourteen non-MDA5 treated patients in combination 
with conventional immunosuppressant therapy has been identified
9
. Ten of them had the 
amyopathic clinical form. All the fourteen patients were initially treated with 
methylprednisolone combined with cyclophosphamide in seven, mycophenolate in one, 
tacrolimus in three, cyclosporine in one, methotrexate in another one and 
immunoglobulins in five. Also, all of them received infliximab at a dose of 5 mg/kg/i.v. 
at week 0, 2, 6 and then every eight weeks. The ten patients (71%) treated in the early 
phase did have a favorable response while the other four (29%) who received infliximab 
after the respiratory failure, died (Level of evidence 3). 
  Despite this data, the expert panel has considered the clinical evidence showing 
that anti-TNF agents may cause serious ILD and, therefore, cannot recommend 
infliximab use in the therapeutic management of these ILD’s patients. 
 
Recommendation 10: Although pirfenidone has been added to conventional 
immunosuppressant treatment in DM-associated subacute interstitial pneumonia with 
pulmonary fibrosis, the expert panel may not recommend its use in patients with RPILD 
associated to anti-MDA5 antibodies (Recommendation grade √). 
 Data on the use of antifibrotic agents comes from a prospective study
52
 that 
included 30 patients with CADM-associated RPILD treated with pirfenidone in addition 
to conventional immunosuppressive treatment (glucocorticoids, cyclosporine and 
mycophenolate) compared with a historical cohort of 27 patients treated with 
conventional therapy. Twenty-two of 30 patients from the pirfenidone-treated group 
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were MDA5 positive versus 4 of 27 patients of the control group. Overall, mortality in 
the pirfenidone-treated group was lower although did not reach statistical significance 
compared with the control group (36.7% vs. 51.9%, p=0.223). An analysis of the 
subgroup of patients with acute ILD (<3 month) (n=30) disclosed identical mortality for 
case and control groups (50% vs. 50%, respectively; p=0.386). However, in patients 
with subacute ILD (3 to 6 month) (n=19), the mortality in pirfenidone-treated patients 
was lower than that of the control group (90% vs. 44%, p=0.045). A subgroup analysis 
describing only MDA-5 patients was not performed. No serious adverse events were 
described (Level of evidence 3). 
 Based on all the previous recommendations, the expert panel proposes two flow 
charts for the diagnosis and treatment (Figures 1 and 2, respectively) of RPILD in 
patients with anti MDA5 antibodies.  
 
Summary and Conclusions  
 Medical literature searching discloses a generally poor prognosis and bad 
outcome in patients with DM who are positive to anti-MDA5 antibodies and develop a 
RPILD. The small number of patients with this syndrome precludes performing 
randomized clinical trials to know which would be the best treatment for this 
catastrophic situation. These recommendations are based on observational studies, 
mainly cohort studies and case reports, therefore the level of scientific evidence is not 
higher than 3. We have completed them summing up the experience of the clinicians 
from different specialties who participated in the task force (clinical recommendations 
by the expert panel). 
 However, this study has a series of limitations. First, the largest number of 
reports from Japan may have skewed our interpretation of the data towards the 
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treatment modalities and practices favored in this region. Second, none of the studies 
identified have a randomized clinical trial design to meet the research objective. They 
correspond to open studies, case series or case reports and include a small number of 
patients. Third, systematic reviews are susceptible to problems like reporting and 
selection bias, incomplete outcome data, confounding by indication and local trends in 
medical practices, among others.  
 Considering these limitations, there is a consensus to treat these patients from 
the onset with a combination therapy that, besides glucocorticoids, includes 
immunosuppressive drugs such as calcineurin antagonists, and following the experience 
from Asian cohorts, adding cyclophosphamide as a third drug. Nevertheless, this 
combination therapy approach is not always enough to get good outcome and to date, 
more than half of the patients follow a fatal course.  Then, adding on or switching 
immunosuppressants could be a plausible option; monoclonal antibodies such as 
basiliximab, rituximab, or new immunosuppressive drugs such as mycophenolate 
mofetil or JAK inhibitors (tofacitinib) may be good options. Moreover, tofacitinib 
combined with glucocorticoids has recently shown to be a promising therapy in the 
early stage of anti-MDA5 positive CADM-ILD
85
 as the six-month survival after ILD 
onset was significantly higher in tofacitinib-treated patients (18 of 18, 100%) than in the  
historical controls who met the same criteria and received conventional therapy (25 of 
32, 78%) (p=0.04). Further studies are warranted to determine its role in anti MDA5 
positive RPILD initial therapy. In addition to the immunosuppressive treatment and 
given the bad outcome that usually experienced these patients, some rescue therapies 
such as plasmapheresis, intravenous immunoglobulins or polymyxin B hemoperfusion 
are also indicated when the patient does not respond adequately in terms of respiratory 
failure. Lastly, extracorporeal membrane oxygenation, as a strategy to allow time for 
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immunosuppressive therapy to be effective or as a bridge therapy to lung 
transplantation, is another option to be considered. 
 
Future research agenda 
Multicenter prospective studies are mandatory to gather enough number of 
patients that allow performing randomized clinical trials, tuning up definitions of 
improvement and outcome, and the proper use of reliable biomarkers to define the risk 
strategy and the best therapeutic option at any moment will undoubtedly contribute to 
the better outcome and improvement of this severe syndrome. On the other hand, a 
consortium that allows going deeper into the knowledge of the intrinsic mechanisms or 
epidemiological issues will be of paramount importance for the understanding of this 
syndrome. 
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Table 1. Recommendations for the treatment of anti-MDA5 positive CADM-RPILD* 
 Set of Recommendations  RG** 
 General management  
1 Patients with CADM-associated rapidly progressive interstitial lung disease anti-MDA5 
(+) should be treated with combination therapy as a first option. 
D 
 Combination therapy   
2 A combination therapy which include glucocorticoids plus a calcineurin inhibitor 
(cyclosporine A or tacrolimus), or triple therapy adding intravenous cyclophosphamide   
to the previous schedule, are both considered good initial alternatives. 
D 
2a Both, cyclosporine A and tacrolimus are considered equally good therapeutic options. The 
choice of any of them will depend on the safety profile and patients’ characteristics. 
√ 
2b Monitoring of calcineurin inhibitors blood levels are recommended in order to adjust 
posology and minimize toxicity. 
√ 
3 When calcineurin inhibitors are not feasible, consider combination therapy with 
glucocorticoids and other immunosuppressive drugs such as cyclophosphamide   and/or 
mycophenolate mofetil☨, or adding rituximab☨ to any one of the previous schedules. 
D 
3a The choice of one of these drugs will depend on the individual characteristics of the 
patient and the clinician experience. 
√ 
 
Therapy for the refractory patient  
4 In patients with CADM-associated RPILD anti-MDA5 (+) who do not respond to 
combination therapy with glucocorticoids plus immunosuppressive drugs, clinicians have 
to take into account the following alternatives: 
 
- Adding one of these immunosuppressive drugs (cyclophosphamide, 
mycophenolate mofetil, rituximab, basiliximab or tofacitinib
∫
) to the current 
therapy. 
D 
- Change one immunosuppressant for another √ 
5 In patients who do not respond to combined immunosuppressive drugs, the use of the 
following alternative rescue therapies, either separate or in a sequential manner, might be 
considered: 
 
- Polymyxin B hemoperfusion D 
- Plasmapheresis D 
- Intravenous immunoglobulins √ 
6 Assistance with ECMO should be considered in patients with life threatening severe and 
refractory respiratory insufficiency in order to maintain the patient alive while waiting for 
a clinical response to intensive and combined immunosuppressive treatment or as a bridge 
to lung transplantation. 
√ 




Lung transplantation should be considered as a therapeutic option in patients with 
refractory RPILD associated to anti-MDA5. Early referral for transplant eligibility 
assessment is recommended at the time of ILD diagnosis. 
√ 
 Other treatment options  
8 Azathioprine, methotrexate and leflunomide are not recommended for the treatment of 
RPILD associated to anti-MDA5. 
√ 
9 Infliximab is not recommended in MDA-5 associated RPILD treatment √ 
10 Although pirfenidone has been added to conventional immunosuppressant treatment in 
CADM-associated subacute interstitial pneumonia with data of pulmonary fibrosis, the 







*Level of evidence was 3 in all the recommendations.   Avoid its administration in young female or 
male who are willing to have offspring. ☨ Avoid its administration in women prone to be pregnant due to 
the risk of fetal embryopathy. ∫ There is not available data on the safety of combined therapy with 
biologic agents and tofacitinib. Abbreviations: R, Recommendation. RG, Recommendation Grade based 
on SIGN methodology, see Appendix 1. RPILD, Rapidly Progressive Interstitial Lung Disease. MDA5, 
Melanoma Differentiation-Associated protein 5. Anti-MDA5, anti-MDA5 antibodies. ECMO, 
Extracorporeal Membrane Oxygenation. 
** Appendix 1. 
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Table 2. Reported therapies in anti-MDA5 positive CADM associated RPILD 
Therapy Dose, schedule and route of administration 
Prednisone/prednisolone1 0.5-1 mg/kg/day p.o. 
Pulsed 
methylprednisolone1 
500 mg-1 gr/day (x3 consecutive days) i.v. 
Cyclosporine A2 2-5 mg/kg/day p.o. or i.v. 
Tacrolimus3 0.06-0.075 mg/kg/day p.o. 
Cyclophosphamide 0.5-1 gr/m2/2-4 weeks i.v. 
Azathioprine4 2-3 mg/kg/day p.o. 
Leflunomide5 10-20 mg/day p.o. 
Methotrexate6 Up to 25 mg/week p.o. or s.c. 
Mycophenolate mofetil 1-3 g/day p.o. 
Basiliximab 20 mg/week (x2) i.v. 
Infliximab 5 mg/kg i.v. at week 0, 2, 6 and every 8 weeks  
Rituximab 
350-375 mg/m2/week (x2-4) i.v. or 
1 gr/2 week (x2) i.v. 
Tofacitinib 5 mg b.i.d. p.o. 
Pirfenidone 267 mg t.i.d. p.o. 
Immunoglobulin 0.4 g/kg/5 days i.v. 
Polymyxin B  
and plasmapheresis 
Hemoperfusion with polymyxin B at a flow rate of 100 
ml/h for 3 h/day (x2) and plasmapheresis with 3.5 l of 







 Corticosteroids as initial or induction/rescue therapy. 
2
 To achieve a blood level of 1,000 ng/mL during 
induction therapy, if possible. 3 To achieve a blood level of 10-15 ng/mL during induction therapy, if 
possible.
 4
 Depending on thiopurine methyl transferase activity. 5 Dose not reported. 
6
 Not administered 
in MDA5 associated RPILD. p.o.: per os. i.v.: intravenous. s.c.: subcutaneous; bid: twice in a day. tid: 
three in a day. 
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Table 3. Research supporting the role of combined therapy, with glucocorticoids plus 
either cyclophosphamide or calcineurin inhibitors or triple therapy with the three of 
them, for the treatment of anti MDA5 positive rapidly progressive interstitial lung 




Type of study 
 







































































































GC, glucocorticoids; CYC, cyclophosphamide; CNI, calcineurin inhibitors; RP-ILD, 
rapidly progressive interstitial lung disease. *Number of patients treated with each 
combination not specified. ✝  2 patients with chronic NI. 
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Figure 1. Diagnosis of RPILD in patients with anti MDA5 antibodies. 
*Combined therapy with glucocorticoids and calcineurin antagonists is recommended specially if 
some risk factors are present (>60 years old, hyperferritinemia >500 nm/mL, C reactive protein > 1 
mg/dl) 
HRCT, High Resolution CT Scan. PFT, Pulmonary Function Tests. RP-ILD, Rapidly Progressive 
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Figure 2. Treatment of RPILD in patients with anti MDA5 antibodies. 
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Appendix 1. Levels of evidence and grades of recommendation 
 




Studies classified as 1- 





times, the development group finds important practical aspects that must be highlighted and for which no 
scientific evidence has been found. In general, these cases are related to some aspects of the treatment 
that nobody would normally question and they are evaluated as points of “good clinical practice”. 
 
Appendix 2. Flow chart with the results of the literature search 
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